Back to discover
Disease

Botulism

Late-stage therapeutic development
Also known as botulism poisoning, infection due to Clostridium botulinum, foodborne botulism (subtype), infant botulism (subtype)+4 more

botulism poisoning, infection due to Clostridium botulinum, foodborne botulism (subtype), infant botulism (subtype), food poisoning due to Clostridium botulinum, foodborne botulism, intoxication with Clostridium botulinum toxin, wound botulism (subtype).

8
Clinical trials
12
Associated genes
4
Related proteins
Current focus
Synaptosomal-associated 25 biologySynaptotagmin-1 biologyTherapeutic development

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial with recent milestones (1 completed or reporting results).
  • 1 industry development reported.
Clinical Milestones1View
Results posted 1
Industry & Market1View
Activity timeline2

Clinical trials

6 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
8
All trials
0
Active
2
Late-stage
6
Completed
Recently completed

Tolerability and Immunogenicity of a Single 40-µg Dose of Recombinant Botulinum Vaccine A/B (rBV A/B) for the Production of BabyBIG® in Volunteers With Existing Botulinum Immunity

Phase 2 · Completed · California Department of Public Health

A Proof of Concept Study of the Effect of Amifampridine (Firdapse®) on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA (Botox®, BTX-A)

Phase 1 · Completed · Wake Forest University Health Sciences

A Phase I, Double-Blind, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1633 vs Placebo Administered Intravenously in Healthy Adults

Phase 1 · Completed · National Institute of Allergy and Infectious Diseases (NIAID)

Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism

Phase 2/3 · Completed · Centre Hospitalier Universitaire, Amiens

A Phase 2, Randomized, Double Blind, Placebo-Controlled, Multicenter Study to Evaluate Safety, Dosing Schedule and Antibody Kinetics of Recombinant Botulinum Vaccine A/B, rBV A/B-40, in Healthy Adults

Phase 2 · Completed · DynPort Vaccine Company LLC, A GDIT Company

Study of Human Botulism Immunoglobulin in Infants With Botulism

N/A · Completed · California Department of Health Services

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

SV2A0.58SV2B0.58SV2C0.57SYT10.55VAMP20.53SNAP250.51VAMP10.50SYT20.50STX1A0.37STX1B0.37CKMT1A0.05FGF110.04

Disease biology

4 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Synaptic vesicle glycoprotein 2Avia SV2A0.58Synaptotagmin-1via SYT10.55Vesicle-associated membrane protein 2via VAMP20.53Synaptosomal-associated protein 25via SNAP250.51

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A disease caused by potent protein NEUROTOXINS produced by CLOSTRIDIUM BOTULINUM which interfere with the presynaptic release of ACETYLCHOLINE at the NEUROMUSCULAR JUNCTION. Clinical features include abdominal pain, vomiting, acute PARALYSIS (including respiratory paralysis), blurred vision, and DIPLOPIA. Botulism may be classified into several subtypes (e.g., food-borne, infant, wound, and others). (From Adams et al., Principles of Neurology, 6th ed, p1208)

Synonyms

botulism poisoning, infection due to Clostridium botulinum, foodborne botulism (subtype), infant botulism (subtype), food poisoning due to Clostridium botulinum, foodborne botulism, intoxication with Clostridium botulinum toxin, wound botulism (subtype)

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.